SAB Bio Reveals New Clinical and Mechanistic Findings from SAB-142 Phase 1 Trial in Adults with Established Autoimmune Type 1 Diabetes at IDS 2026
Clinical Trial Announcement: SAB Biotherapeutics has presented additional clinical and mechanistic data from its SAB-142 Phase 1 trial.
Target Patient Group: The trial focuses on adult patients with established Type 1 diabetes.
Trade with 70% Backtested Accuracy
Analyst Views on SABSW
No data
About the author
SAB Bio Reveals New Clinical and Mechanistic Findings from SAB-142 Phase 1 Trial in Adults with Established Autoimmune Type 1 Diabetes at IDS 2026
Clinical Trial Announcement: SAB Biotherapeutics has presented additional clinical and mechanistic data from its SAB-142 Phase 1 trial.
Target Patient Group: The trial focuses on adult patients with established Type 1 diabetes.
SAB BIO Announces Financial Results for Third Quarter and Key Business Updates
Initiation of SAFEGUARD Trial: SAB Biotherapeutics has launched the registrational Phase 2b SAFEGUARD trial for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, with plans to dose the first patient by year-end.
Clinical Data Presentation: Recent presentations at EASD and ISPAD highlighted the favorable safety profile and multi-specific mechanism of action of SAB-142, reinforcing its potential as a disease-modifying treatment for T1D.
Financial Position: As of September 30, 2025, SAB Biotherapeutics reported a strong cash position of $161.5 million, enabling continued investment in the SAB-142 program and other research activities.
Upcoming Milestones: The company is on track to share additional data from the SAFEGUARD trial in the second half of 2027 and finalize Phase 1 study results by the end of this year.
SAB BIO Showcases Data Through Various Presentations at EASD
SAB-142 Phase 2b Study Initiation: SAB Biotherapeutics has launched its Phase 2b SAFEGUARD study for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, and engaged with T1D thought leaders at the EASD Annual Meeting.
Validation of SAB-142's Efficacy: Presentations at EASD highlighted SAB-142's potential as a best-in-class immunotherapy for T1D, demonstrating a clinically validated mechanism of action and favorable pharmacokinetic profile, while also confirming the disease-modifying effects of rabbit ATG in a related study.
SAB BIO Announces Oversubscribed $175 Million Private Placement
Funding Announcement: SAB BIO has secured $175 million in a private placement financing, with participation from strategic and new investors, to fund its Phase 2b SAFEGUARD study for delaying progression of autoimmune type 1 diabetes (T1D) in newly diagnosed patients.
Financial Outlook: The proceeds are expected to extend the company's cash runway into mid-2028, with potential additional gross proceeds of up to $284 million if milestone-based warrants are fully exercised.
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
Financial Performance and Developments: SAB BIO reported a net loss of $5.2 million for Q1 2025, with cash reserves decreasing to $12.9 million. The company is focusing on cost-saving initiatives and has achieved compliance for its manufacturing process in Europe.
Clinical Progress: The company announced positive Phase 1 data for its lead product, SAB-142, aimed at delaying type 1 diabetes progression, and completed patient dosing in the final cohort of the Phase 1 clinical study.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
Phase 1 Enrollment Completion: SAB BIO has completed enrollment for its Phase 1 study of SAB-142, a treatment aimed at delaying type 1 diabetes (T1D), with no observed serum sickness and is on track for topline data by the end of the year.
Financial Overview: The company reported a net loss of $10.3 million for Q3 2024, with increased research and development expenses as it advances its T1D program, while maintaining sufficient cash to fund operations into 2026 if outstanding warrants are exercised.
SAB Bio Reveals New Clinical and Mechanistic Findings from SAB-142 Phase 1 Trial in Adults with Established Autoimmune Type 1 Diabetes at IDS 2026
Clinical Trial Announcement: SAB Biotherapeutics has presented additional clinical and mechanistic data from its SAB-142 Phase 1 trial.
Target Patient Group: The trial focuses on adult patients with established Type 1 diabetes.
SAB BIO Announces Financial Results for Third Quarter and Key Business Updates
Initiation of SAFEGUARD Trial: SAB Biotherapeutics has launched the registrational Phase 2b SAFEGUARD trial for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, with plans to dose the first patient by year-end.
Clinical Data Presentation: Recent presentations at EASD and ISPAD highlighted the favorable safety profile and multi-specific mechanism of action of SAB-142, reinforcing its potential as a disease-modifying treatment for T1D.
Financial Position: As of September 30, 2025, SAB Biotherapeutics reported a strong cash position of $161.5 million, enabling continued investment in the SAB-142 program and other research activities.
Upcoming Milestones: The company is on track to share additional data from the SAFEGUARD trial in the second half of 2027 and finalize Phase 1 study results by the end of this year.
SAB BIO Showcases Data Through Various Presentations at EASD
SAB-142 Phase 2b Study Initiation: SAB Biotherapeutics has launched its Phase 2b SAFEGUARD study for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, and engaged with T1D thought leaders at the EASD Annual Meeting.
Validation of SAB-142's Efficacy: Presentations at EASD highlighted SAB-142's potential as a best-in-class immunotherapy for T1D, demonstrating a clinically validated mechanism of action and favorable pharmacokinetic profile, while also confirming the disease-modifying effects of rabbit ATG in a related study.
SAB BIO Announces Oversubscribed $175 Million Private Placement
Funding Announcement: SAB BIO has secured $175 million in a private placement financing, with participation from strategic and new investors, to fund its Phase 2b SAFEGUARD study for delaying progression of autoimmune type 1 diabetes (T1D) in newly diagnosed patients.
Financial Outlook: The proceeds are expected to extend the company's cash runway into mid-2028, with potential additional gross proceeds of up to $284 million if milestone-based warrants are fully exercised.
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
Financial Performance and Developments: SAB BIO reported a net loss of $5.2 million for Q1 2025, with cash reserves decreasing to $12.9 million. The company is focusing on cost-saving initiatives and has achieved compliance for its manufacturing process in Europe.
Clinical Progress: The company announced positive Phase 1 data for its lead product, SAB-142, aimed at delaying type 1 diabetes progression, and completed patient dosing in the final cohort of the Phase 1 clinical study.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
Phase 1 Enrollment Completion: SAB BIO has completed enrollment for its Phase 1 study of SAB-142, a treatment aimed at delaying type 1 diabetes (T1D), with no observed serum sickness and is on track for topline data by the end of the year.
Financial Overview: The company reported a net loss of $10.3 million for Q3 2024, with increased research and development expenses as it advances its T1D program, while maintaining sufficient cash to fund operations into 2026 if outstanding warrants are exercised.
